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Abstract
Heart failure (HF) is a global public health problem, and outcomes remain poor, especially among ethnic
minority populations. Medication adherence can improve heart failure outcomes but is notoriously low. The
purpose of this secondary analysis of data from a prospective cohort comparison study of adults with heart
failure was to explore differences in predictors of medication nonadherence by racial group (Black vs. White)
in 212 adults with heart failure. Adaptive modeling analytic methods were used to model HF patient
medication nonadherence separately for Black (31.7%) and White (68.3%) participants in order to investigate
differences between these two racial groups. Of the 63 Black participants, 33.3% had low medication
adherence, compared to 27.5% of the 149 White participants. Among Blacks, 16 risk factors were related to
adherence in bivariate analyses; four of these (more comorbidities, lower serum sodium, higher systolic blood
pressure, and use of fewer activities compensating for forgetfulness) jointly predicted nonadherence. In the
multiple risk factor model, the number of risk factors in Black patients ranged from 0 to 4, and 76.2% had at
least one risk factor. The estimated odds ratio for medication nonadherence was increased 9.34 times with
each additional risk factor. Among White participants, five risk factors were related to adherence in bivariate
analyses; one of these (older age) explained the individual effects of the other four. Because Blacks with HF
have different and more risk factors than Whites for low medication adherence, interventions are needed that
address unique risk factors among Black patients with HF.
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Abstract
Heart failure (HF) is a global public health problem, and outcomes remain poor, especially among 
ethnic minority populations. Medication adherence can improve heart failure outcomes but is 
notoriously low. The purpose of this secondary analysis of data from a prospective cohort 
comparison study of adults with heart failure was to explore differences in predictors of 
medication nonadherence by racial group (Black vs. White) in 212 adults with heart failure. 
Adaptive modeling analytic methods were used to model HF patient medication nonadherence 
separately for Black (31.7%) and White (68.3%) participants in order to investigate differences 
between these two racial groups. Of the 63 Black participants, 33.3% had low medication 
adherence, compared to 27.5% of the 149 White participants. Among Blacks, 16 risk factors were 
related to adherence in bivariate analyses; four of these (more comorbidities, lower serum sodium, 
higher systolic blood pressure, and use of fewer activities compensating for forgetfulness) jointly 
predicted nonadherence. In the multiple risk factor model, the number of risk factors in Black 
patients ranged from 0 to 4, and 76.2% had at least one risk factor. The estimated odds ratio for 
medication nonadherence was increased 9.34 times with each additional risk factor. Among White 
participants, five risk factors were related to adherence in bivariate analyses; one of these (older 
age) explained the individual effects of the other four. Because Blacks with HF have different and 
more risk factors than Whites for low medication adherence, interventions are needed that address 
unique risk factors among Black patients with HF.
Keywords
Heart failure; medication adherence; self-care; race; disparities
Heart failure (HF) is a global public health issue, with a prevalence of over 5.7 million cases 
in the United States (US; Mozaffarian et al., 2014) and over 23 million cases worldwide 
(Bui, Horwich, & Fonarow, 2011). In the US, the highest prevalence of HF is in Blacks 
(3.6%), followed by Whites (2.4%) and Hispanics (2.3%; Heidenreich et al., 2013). Overall, 
1 in 9 deaths is attributed to HF (Mozaffarian et al., 2014). Ethnic minority patients have a 
2.5 times greater risk of HF-related mortality, which is especially pronounced for Black 
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males (81.9 national death rate per 100,000 people, compared to 62.1 for White males, and 
58.7 for Black females compared to 43.2 for White females; Bahrami et al., 2008).
Heart failure is a major contributor to the cost of health care, predominately because of 
hospitalizations (Heidenreich et al., 2013). Over the last thirty years, hospitalizations for HF 
have nearly tripled to more than 1 million in 2006; establishing HF as the most common 
cause for hospitalization in the Medicare population (Koelling, Johnson, Cody, & Aaronson, 
2005). Compared to Whites, the likelihood of a HF hospitalization is estimated to be 1.5 
times greater among Blacks and 1.2 times greater among Hispanics (Brown, Haldeman, 
Croft, Giles, & Mensah, 2005).
The reason for this health disparity is complex. Medication nonadherence is one important 
contributor to hospitalization in patients with HF (Riegel & Knafl, 2013). In addition, 
Blacks are more likely than Whites to have diabetes, hypertension and obesity, which 
increase the risk of HF, complicate management and contribute to poorer outcomes 
(Schocken et al., 2008). Low socioeconomic status, which is more common in ethnic 
minority populations, is associated with poor HF outcomes, presumably due to barriers to 
access and utilization of health care services (Schocken et al., 2008). But surprisingly little 
research has explored this disparity, so the purpose of this study was to delve further into 
medication adherence to determine if differences exist that could help to explain the 
disparity in HF outcomes among White and Black patients.
Medication Adherence in Heart Failure
Medication adherence is one of a constellation of self-care behaviors (i.e., adherence to 
treatment regimens, symptom monitoring and symptom management) that can improve HF 
outcomes. Medication nonadherence is defined as doses not taken or taken incorrectly that 
jeopardize the therapeutic outcome (Nichols-English & Poirier, 2000). Nonadherence is 
estimated at 40% to 60% in patients with HF (Wu, Moser, Lennie, & Burkhart, 2008). This 
is particularly concerning because medication adherence has been shown to decrease 
hospitalization (Riegel & Knafl, 2013), decrease the healthcare costs associated with HF 
(Wald & Law, 2003), and improve survival (Wu, Moser, Chung, & Lennie, 2008a).
In an analysis of Medicare patients with HF, Zhang and Baik (2014) found that in 
comparison to White patients, ethnic minority populations, including Black and Hispanic 
patients, were more likely to be nonadherent to common HF medications (i.e., beta-blockers, 
angiotensin-converting enzyme [ACE] inhibitors, and diuretics), which helps to explain their 
increased readmission rates, longer hospital stays and increased mortality (Bagchi, Esposito, 
Kim, Verdier, & Bencio, 2007; Wu, Moser, Chung, et al., 2008a).
Predictors of Nonadherence
The reason for differences in medication adherence among White and Black patients with 
HF is not entirely clear. Predictors of medication nonadherence include socioeconomic 
factors (e.g., income), individual-level factors (e.g., race/ethnicity, age, social support), 
condition-related factors (e.g., comorbid conditions, depression), and provider- or healthcare 
system-related factors (e.g., provider satisfaction, access; Sabate, 2003). Other reasons 
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include forgetfulness (Riegel et al., 2012), perceived lack of benefit (Wu, Moser, Chung, & 
Lennie, 2008b), and cost (Van der Wal & Jaarsma, 2008). Whether the influence of these 
factors differs between White and Black patients with HF has not been explored.
Research to Date
We have conducted a series of studies exploring predictors of medication adherence in HF 
patients. In the first two analyses, we used the World Health Organization dimensions of 
adherence (socioeconomic, condition, therapy, patient, and healthcare system) to focus our 
exploration of contributors to nonadherence (Riegel & Knafl, 2013; Riegel et al., 2012). In 
the third analysis, we tested a wide range of clinical and patient-related variables 
(demographic, social support, self-care, symptoms, and cognition) to avoid omitted variable 
bias (Knafl & Riegel, 2014). In a subsequent study we found that Blacks had poorer 
medication adherence than Whites (Dickson, Knafl, & Riegel, 2015). Therefore, we sought 
to examine how predictors of medication nonadherence differ between White and Black 
patients with HF in order to understand where to focus future interventions aimed at 
improving medication adherence in those patients most vulnerable to poor HF outcomes.
Specifically, this study addressed these research questions:
1. What factors put Black patients with HF at risk for medication nonadherence?
2. What factors put White patients with HF at risk for medication nonadherence?
3. How do these factors differ among Black and White patients with HF?
Methods
Parent Study
The methods used in the larger study have been described in other reports (Riegel & Knafl, 
2013; Riegel et al., 2012). In brief, between 2007 and 2009, 280 adults living in the 
northeastern United States with chronic HF were enrolled into a prospective cohort 
comparison study. A total of 242 adults completed the study.
Cohorts were purposefully varied on the dimensions of cognition, tested with a 
neuropsychological battery (Riegel et al., 2011) and daytime sleepiness assessed with the 
Epworth Sleepiness Scale (Johns, 1992). Inclusion criteria specified that participants have a 
confirmed diagnosis of HF of any type, fluency in English, and visual, hearing and health 
literacy sufficient to actively participate in all testing. All participants met a minimum level 
of cognition screened with the Telephone Interview of Cognitive Status (TICS); anyone with 
a score < 24 was excluded. Further exclusion criteria including major depression, renal 
dialysis, recent history of serious drug or alcohol abuse, imminent death due to terminal 
illness, and working at night because of the emphasis on exploring sleepiness as a predictor 
of self-care.
The instruments were administered and other data were collected in a quiet setting in the 
home by trained research assistants. Institutional Review Board approval was obtained for 
the study and every participant provided written informed consent.
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Measures
Adherence—The Medication Event Monitoring System (MEMS™; MVW Switzerland 
Ltd., Sion, Switzerland) attached to a bottle of medication was used to collect medication 
adherence data objectively from individual patients. The device records the date and time of 
all bottle openings. MEMS data were collected on one medication scheduled to be taken at a 
fixed time, preferably more than once daily. Most patients were willing to use the device for 
one of their cardiac medications (beta blocker 56.7%, angiotensin-converting enzyme 
inhibitor 15.2%), but a wide variety of medicines was monitored. A single medication was 
monitored based on the observation of Cramer et al (1995) that patients usually took doses 
of all their medications simultaneously. That is, if a patient is likely to forget one medicine, 
chances are that he will forget all of them.
Participants were fully informed that the MEMS device captured their medication-taking 
behavior in a computer chip. They were instructed on how to integrate the device into their 
daily routine, even if they routinely used a pill box. MEMS data were collected over the 
entire 6months of the study and downloaded at 3 and 6 months. Participants kept a study 
diary for the MEMS in which they could note openings that were accidental or for another 
purpose (e.g. to fill the container). These deviations were corrected before analysis.
Demographic and clinical variables—Sociodemographic variables, including race, 
were self-reported. Clinical characteristics such as left ventricular ejection fraction, 
laboratory values, and the Charlson Comorbidity Index (Charlson, Pompei, Ales, & 
MacKenzie, 1987) were abstracted from the medical record by registered nurses. Blood 
pressure was measured during the home visit using calibrated equipment. Pulse rate was 
measured at the same time.
Depression—Depression was measured using the Patient Health Questionnaire (PHQ-9; 
Kroenke, Spitzer, & Williams, 2001), a reliable and well-validated measure used frequently 
in HF studies (Masoudi et al., 2004; Sullivan, Newton, Hecht, Russo, & Spertus, 2004). The 
PHQ-9 had a sensitivity of 88% and a specificity of 88% for detecting major depression 
when a score of 10 was compared to professional interviews as the criterion standard 
(Kroenke et al., 2001).
Heart failure self-care—Self-care was measured using the Self-Care of Heart Failure 
Index (SCHFI V6.2), a 22- item measure of self-care maintenance, management, and 
confidence (Riegel, Lee, Dickson, & Carlson, 2009). Construct validity was demonstrated in 
a sample of 659 HF patients. When internal consistency was tested by factor score 
determinacy, all coefficients were >.70, with moderate to high correlations over time in test-
retest reliability testing (Barbaranelli, Lee, Vellone, & Riegel, 2014).
Social support—Social support was measured using the Multidimensional Scale of 
Perceived Social Support (MSPSS). The 12-item MSPSS measures perceived adequacy of 
social support from three sources using a 7-point likert scale. Construct validity was 
demonstrated in a sample of 275 adults and confirmed in subsequent populations (Zimet, 
1988; Zimet, Dahlem, Zimet, & Farley, 1994). Factor analysis confirmed a three-subscale 
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structure of the MSPSS: family, friends and significant others (Zimet et al., 1990). The 
MSPSS has strong alpha coefficients in HF populations (.87 to .91; Dickson, Deatrick, & 
Riegel, 2008; Dickson, McCarthy, Howe, Schipper, & Katz, 2013). In this study, Cronbach 
alphas for the subscales were very strong (.92, .93 and .88); the total scale alpha was .90.
Compensatory activities—The Compensatory Activities Survey was investigator-
designed to assess methods used to compensate for feeling confused or forgetful. 
Participants were asked to indicate how often over the past week they used the following 
five compensatory activities identified from the published literature: 1) keep lists or notes to 
yourself, 2) get help from your wife/husband, children, neighbor, or others, 3) associate 
something you want to remember with something else that you already know or remember, 
4) visualize the thing you want to remember, 5) repeat new things to yourself. An additional 
question asked about other techniques used. Each item was scored never, rarely, sometimes, 
often, frequently or always. For the final “other” activity, nothing else was an additional 
choice. The number of items endorsed was used as the score. The Cronbach alpha for this 
survey was .65.
Cognition—Cognition was assessed using a neuropsychological battery of four tests used 
commonly in patients with HF (Alosco, Spitznagel, Josephson, Hughes, & Gunstad, 2015; 
Miller et al., 2012) that measured attention, processing speed, working memory, and short-
term memory. The Digit Symbol Substitution Test (DSST) is a timed test in which numbers 
are matched with different nonsense symbols. The DSST discriminates age cohorts (Joy et 
al., 2003) and is sensitive to subtle neurocognitive impairment (Hinton-Bayre, Geffen, & 
McFarland, 1997). A poor working memory slows performance and accuracy. The number 
completed in 120 seconds, the number correctly matched, and percent correct were used in 
analysis. Test developers reported test-retest reliability of 0.86 (Gregory, 1999).
The Probed Memory Recall (PMR) test is a free recall measure of verbal learning and 
retention. Four word pairs are studied for 30 seconds. After a 10-minute delay, one word in 
each pair (in a different order) is presented. The task is to recall all four of the paired words 
within one minute. Recall of only two of four words suggests that memory is impaired 
(Dinges, Kribbs, Bates, & Carlin, 1993).
The Trail Making Test is a widely used and sensitive measure of attention and cognitive 
flexibility, a component of executive function (Reitan, 1955), and has shown strong test-
retest reliability (.86 to .94; Wagner, Helmreich, Dahmen, Lieb, & Tadic, 2011). In patients 
with HF, the Trail Making Test has demonstrated relationships to areas of brain pathology as 
assessed by magnetic resonance imaging (Serber et al., 2008). In the Trail Making Test Part 
A, subjects connect randomly numbered and ordered circles, using a pencil, as fast as 
possible in serial order. In Part B, on another worksheet, they are asked to connect the same 
number of consecutively numbered and lettered circles by alternating between numbers and 
letters.
The Letter Number Sequencing subtest of the Wechsler Adult Intelligence Scale—Third 
Edition (WAIS III) is primarily a measure of auditory working memory and attention, 
although it also measures executive function. In this task, participants sequentially order a 
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series of numbers and letters that have been orally presented in a specified random order. 
They must first remember the numbers and letters and then reorganize them into ascending 
or alphabetical order. Slowed processing speed, inability to remember earlier responses, and 
reduced capacity to ignore irrelevant information all contribute to decrements in 
performance. The internal consistency coefficient is .82 (Silva, 2008) and test-retest 
reliability is .75 (Alosco et al., 2015).
Data Analysis
For this analysis the variables were organized into six categories: 1) demographics (e.g., age, 
gender), 2) social support (e.g., marital status, Multidimensional Scale of Perceived Social 
Support score), 3) clinical (e.g., comorbidities, serum sodium), 4) self-care (e.g., Self-Care 
of Heart Failure Index, HF knowledge), 5) symptoms (e.g., NYHA class, depression), and 6) 
cognition (e.g., DSST, Compensatory Activities Survey).
Adaptive modeling of adherence outcome—In our first paper using the MEMS data, 
standard summary measures of the MEMS data were used, for example, percentage of 
prescribed doses that were taken (% PDT; Riegel et al., 2012). Subsequently, adaptive 
modeling methods (Knafl et al., 2010) were used to analyze available MEMS data more 
fully (Riegel & Knafl, 2013). These methods were used to identify individual-patient 
adherence patterns represented by possibly nonlinear mean adherence and adherence 
variability curves over time. The adherence patterns were normalized by prescribed rates so 
that the ideal pattern had constant mean adherence of 1 and constant adherence variability of 
0 (although no patients had adherence variability of 0). Then, these individual-patient 
adherence patterns were clustered into adherence types or groups of participants with similar 
adherence patterns.
Seven adherence types were identified, but hospitalization within 6 months was best 
predicted by combining the seven types into the dichotomous predictor of poor adherence 
(i.e., three of the clusters with adherence deteriorating to zero adherence or nearly zero over 
time) versus better adherence (i.e., four clusters with moderate to high adherence over the 
entire measurement period). This adaptively-determined dichotomized outcome served as 
the nonadherence outcome for the analyses reported in this article.
Model development of predictors of nonadherence—Logistic regression models 
for medication nonadherence were generated using adaptive modeling methods (Knafl et al., 
2010). These methods use k-fold likelihood cross-validation (LCV) scores to evaluate and 
compare models, with larger LCV scores indicating better models. Observations are 
separated into k disjoint subsets, called folds, using random numbers. For each fold, 
parameter estimates for a given model are computed using the data in all the other folds. 
These deleted parameter estimates are then used to compute likelihoods for the folds, which 
are then normalized by the sample size and combined into the LCV score for the associated 
model. For reported analyses, LCV scores are based on 10 folds and on likelihoods for 
logistic regression models.
LCV scores for two models can be compared with LCV ratio tests, analogous to likelihood 
ratio tests, but conducted using the percent decrease for the smaller LCV score compared to 
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the larger LCV score. LCV-based comparisons provide more objective assessments of 
effects of individual predictors in comparison to significance tests of slopes for those 
predictors. Moreover, they can be more conservative, identifying predictors as having 
insubstantial effects when the associated test for zero slope is significant (see the Results for 
examples), and so are similar in effect to multiple comparisons procedures.
Each data set has an associated cutoff for a substantial (distinct or significant) percent 
decrease in LCV scores that depends on the number of observations in that data set. A 
percent decrease greater than this cutoff indicates that the model with the smaller LCV score 
is improved upon substantially by the model with the larger LCV score. When the model 
with the smaller LCV score is simpler, it is preferable. A percent decrease less than or equal 
to this cutoff indicates that the model with the smaller LCV score is a competitive 
alternative to the model with the larger LCV score. For example, when the constant model is 
compared to a model based on a single risk factor, a percent decrease in LCV scores less 
than the cutoff for the data indicates that this risk factor has an insubstantial effect on 
medication nonadherence. In the present analysis, cutoffs for a substantial percent decrease 
in the LCV scores were 3.00% for Blacks and 1.28% for Whites.
Separate analyses for the Black and White subgroups were chosen over moderation analyses 
of the combined data. When x is a possible predictor, a moderation analysis would include 
both the predictor x and its interaction with being Black. This approach assumes that the 
predictor has an effect for Whites that differs from the effect for Blacks. However, it is 
possible that x has an effect only for Blacks and not for Whites, or vice versa. Subgroup 
analyses were chosen because they allowed for different predictors for Blacks and Whites.
Dichotomous risk factors for medication nonadherence were identified separately for Black 
and White participants using the following process: 1) Bivariate models were used to 
identify risk factors with an odds ratio (OR) > 1 for medication nonadherence. 2) Identified 
risk factors with significant (I<.05) slopes were combined adaptively into a multiple risk 
factors model. 3) The adaptive multiple risk factors model was used to generate the 
associated risk index model for medication nonadherence, based on the count of that 
model’s risk factors. Interactions between risk factors were not considered in these subgroup 
analyses (as they were in analyses of the full data; Knafl & Riegel, 2014) because 
meaningful interaction results were unlikely given the modest subgroup sample sizes.
In step 1, categorical variables were used unchanged. In subsequent analysis steps, the 
predictors, whether ordinal or continuous, were dichotomized as follows. A predictor’s 
observed values were split into two sets, using each of those observed values as a threshold 
for low versus high ranges of values. Only cases with at least 10% of the observations in 
each range of values were considered. The selected threshold was the one generating the 
best LCV score for predicting medication nonadherence. Cases with values producing an OR 
>1 were treated as having the risk factor. Observations with missing values were 
conservatively assigned to the non-risk factor range of values. Information can be lost when 
a predictor is categorized into two levels, so LCV scores for categorized and uncategorized 
predictors were compared. Comparisons were limited to predictors with no missing values, 
because the compared LCV scores would have been computed for the same set of data.
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In step 2, a model was selected using the adaptive modeling process of Knafl et al. (2010). 
Risk factors under consideration for inclusion in the model were added systematically to the 
model using LCV scores to decide which risk factor to add next. Then this expanded model 
was contracted, removing any extraneous risk factors. LCV ratio tests were used to decide 
whether to continue contracting the model or stop the contraction.
In step 3, the count of the number of risk factors in the adaptively generated multiple risk 
factors model was used as a risk index variable for predicting medication nonadherence.
Results
Sample
Usable MEMS data were available for 218 (90.1%) of the 242 participants who completed 
the parent study. Of these 218 participants with MEMS data, 149 (68.3%) were White and 
69 (31.7%) were non-White. Of those who were non-White, the vast majority was Black (63 
or 91.3% out of 69); 4 were Hispanic and 2 were American Indian. Therefore, we focused 
our analysis on the 212 White and Black participants.
Table 1 provides a comparison of Blacks and Whites on selected demographic 
characteristics. Black participants were significantly more likely than White participants to 
be retired, unemployed, or disabled, to report insufficient income, to have government or no 
insurance, and to be single, divorced, separated, or widowed. Black participants had 
significantly fewer years of education on average.
Table 2 provides a comparison of Blacks and Whites on selected clinical variables. Blacks 
were significantly more likely to perceive their general health as poor and to have severely 
limited functioning (NYHA functional class IV). Black participants had significantly more 
comorbid conditions, took more medications, and took more doses of those medications 
each day.
Low adherence based on MEMS is often defined as percent doses taken (% PDT) < 88% 
(Wu et al., 2009). A total of 87 (41.0%) of the 212 participants had % PDT ≥ 88%, with 27 
(28.7%) of these hospitalized in 6 months. The remaining 63 (29.7%) participants had % 
PDT < 88%, and better adherence as determined adaptively, with 18 (28.6%) hospitalized in 
6 months. A total of 62 (29.2%) of the 212 participants had poor adaptively measured 
adherence, with 35 of these 62 (56.5%) of these hospitalized within six months. All these 
participants also had poor adherence when traditionally measured as % PDT < 88%. The 
hospitalization rates were almost the same for these latter two groups, demonstrating that 
poor adherence determined adaptively is a more sensitive indicator than % PDT < 88%. 
Consequently, % PDT was not considered in further analyses.
When examined using %PDT, Black participants were significantly more likely than White 
participants to have this type of poor adherence (p=.001; 76.2% vs. 51.7%). However, when 
poor adherence was determined adaptively, Black participants were no more likely than 
Whites to have poor adherence (p=.395; 33.3% vs. 27.5%).
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Risk Factors for Medication Nonadherence for Black Participants
Table 3 contains results for individual risk factor analyses of medication nonadherence (as 
determined adaptively) for Black participants. There were 16 individually significant (p≤.
05) risk factors. The constant model generated a substantial percent decrease in the LCV 
scores (greater than the previously determined cutoff of 3.00%) for 10 of these 16 risk 
factors (LCV scores not reported), indicating that LCV ratio tests can generate conservative 
results. The individual risk factor model based on more comorbidities had the best LCV 
score of 0.54732 among all the individual risk factor models of Table 3.
Of the 15 risk factors of Table 3, 10 could be analyzed as continuous or ordinal predictors 
(not counting living alone) as well as risk-factor categories and had no missing values, so 
these 10 risk-factor models could be compared to models linear in the associated predictors, 
to assess the impact of categorizing these variables. For all 10 of these predictors, the 
categorized risk-factor model generated the better LCV score than the associated linear-
predictor model. Moreover, for five of these predictors (blood urea nitrogen, creatinine, 
serum sodium, PHQ total score, and DSST score), the linear-predictor model generated a 
substantially lower percent decrease in the LCV score. This finding indicated that adaptively 
categorizing these variables into two-level risk factors provided substantially better 
predictions of poor adherence than that obtained with standard linear-predictor modeling.
Table 4 contains results for the adaptive multiple risk factors model based on the 16 
significant individual risk factors of Table 3. This model included four risk factors jointly 
predicting poor adherence: more comorbidities, lower serum sodium, higher systolic blood 
pressure, and fewer methods of compensating for forgetfulness. This model had a LCV 
score of 0.61437, which was a substantial improvement over the individual risk factor model 
with the best LCV, with a substantial percent decrease of 10.91%. Consequently, the 
multiple risk factors model for Black participants provided a substantial improvement over 
all the individual risk factor models. This model had a c-index (the same as the area under 
the receiver-operating characteristics [ROC] curve) of 0.86, which is considered excellent 
discrimination (Hosmer & Lemeshow, 2000). The Nagelkerke R2 was 50.4%.
Numbers of risk factors from the multiple risk factor model for the 63 Black patients ranged 
from 0 to 4, with 15 (23.8%) patients having none of the risk factors, 27 (42.9%) patients 
having 1, 17 (27.0%) having 2, 3 (4.8%) patients having 3, and 1 (1.6%) patient having all 4 
risk factors. For the 15 patients with 0 risk factors, none were nonadherent; for the 27 
patients with 1 risk factor, 22.2% were nonadherent; for the 17 patients with 2 risk factors, 
64.7% were nonadherent; for the 4 patients with 3 or 4 risk factors, 100% were nonadherent 
to the medication regimen.
To assess the possibility of collinearity between these four risk factors, logistic regression 
models were computed predicting each of them as a function of the other three. The largest 
Nagelkerke R2 value for these models was 2.2%. Thus, collinearity was not a problem for 
the multiple risk factors model.
When the number of these 4 risk factors, treated as a risk index, was used as a single 
predictor of nonadherence, this risk index model had a LCV score of 0.64523 and improved 
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substantially on the multiple risk factors model, with a percent decrease in the LCV score of 
4.78%. The c-index for this risk index model was also excellent at .85. The estimated OR for 
medication nonadherence with each unit increase in the risk index count variable was 9.34 
(95% CI 3.04 to 28.7; p<.001). That is, the odds of nonadherence increased by 9.34 times 
with each additional risk factor.
Risk Factors for Medication Nonadherence for White Participants
Table 5 contains results for individual risk factor analyses of medication nonadherence for 
White participants. There were 5 significant (p≤.05) individual risk factors (age, 
comorbidities, months since HF diagnosis, total medication doses, cognition). The constant 
model generated a substantial percent decrease in the LCV scores (greater than the cutoff of 
1.28% for the White data) for 2 (40.0%) of these 5 risk factors (LCV scores not reported), 
indicating once again that LCV ratio tests can generate conservative results.
Of the five risk factors of Table 5 based on continuous or ordinal predictors, three of them 
had no missing values and could be compared to categorized risk factors. In all three cases, 
the risk-factor model generated the better LCV score than the associated linear-predictor 
model. For two (66.7%) of these predictors (age and TMTB score), the linear-predictor 
model generated a substantially lower percent decrease in the LCV score, indicating that 
adaptively categorizing these variables into two-level risk factors provided substantially 
better predictions of poor adherence than was obtainable through standard linear-predictor 
modeling.
The adaptive multiple risk factors model based on the five individually significant risk 
factors of Table 5 identified only one risk factor: older age, which was the individual risk 
factor model with the best LCV score of 0.56240 among all the individual risk factor 
models. With only one risk factor, collinearity or a risk index model could not be 
considered. The c-index for this singleton predictor model was .62, less than the cutoff of .
70 for acceptable discrimination (Hosmer & Lemeshow, 2000). The Nagelkerke R2 was 
7.4%.
Discussion
Although others have reported differences in medication adherence by race/ethnicity or 
identified the predictors of medication adherence among patients with HF in general, this 
analysis is the first, to our knowledge, to differentiate the predictors of adherence by racial 
group. Our findings that Blacks have more and different risk factors for poor medication 
adherence is important because it provides specific guidance on where to focus interventions 
aimed at improving medication adherence and related HF outcomes. We found that Blacks 
had four risk factors that jointly predicted nonadherence (more comorbidities, lower serum 
sodium, higher systolic blood pressure, and use of fewer activities compensating for 
forgetfulness). Among White participants, only one risk factor (older age) explained the 
individual effects of the other four, which is consistent with evidence that medication 
nonadherence is common in the elderly (MacLaughlin et al., 2005).
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Comorbidity was identified as one of the four major risk factors among Blacks. Comorbidity 
is extremely common in patients with HF (Braunstein et al., 2003) and adds complexity to 
the medication regimen required of patients, in part due to the number of medications, drug 
interactions, and side effects (Mastromarino et al., 2014). Multiple chronic conditions have 
been shown to complicate self-care when patient care is fragmented (Dickson, Buck, & 
Riegel, 2011). When faced with uncertainty about medication or unpleasant medication side 
effects, patients with HF described the influence of self-efficacy on their daily self-care, 
including decisions about which medications to take (Dickson, Buck, & Riegel, 2013). 
Patients with multiple chronic conditions also experience more functional limitations that 
make daily activities difficult, such as traveling to pick up medicines, remembering to take 
them, and symptom recognition and management (Bakas, Pressler, Johnson, Nauser, & 
Shaneyfelt, 2006). Because medication adherence is essential to HF outcomes (Riegel & 
Knafl, 2013; Wu, Moser, Chung, et al., 2008a), our results suggest that Blacks may be more 
vulnerable to the burden of multiple chronic conditions than Whites. Focused efforts to 
integrate care and interventions to facilitate medication adherence are essential.
In Whites both comorbidity and cognition were individual determinants of nonadherence, 
but their influence on adherence was explained away by older age in the final analysis. That 
is, in Whites, nonadherence was related to age in a strong enough way that the effects of 
comorbidity and cognition on adherence were no longer of substance. This finding was 
surprising to us because it suggests that there is an element of aging itself, beyond 
comorbidity and cognition, that is influencing nonadherence. Further research is needed to 
determine the aspects of aging that are associated with medication nonadherence.
A lower level of serum sodium was a predictor of nonadherence in Blacks. At a cut-point of 
≤ 139 meq/L, these serum sodium levels did not qualify as true hyponatremia. However, 
because fluid retention stimulates atrial natriuretic peptide secretion and the loss of sodium, 
a lower level of serum sodium is an indicator of the severity of cardiac dysfunction 
(Gheorghiade et al., 2007). Thus, these results suggest that either the sicker Black patients 
are those who are most likely to be nonadherent, or those who are nonadherent are most 
likely to become sicker. To the best of our knowledge, this is the first study to demonstrate a 
relationship between serum sodium and poor medication adherence.
Interestingly, higher systolic BP was one of the four joint predictors of poor medication 
adherence in Blacks but not in Whites. Previously we reported that Blacks were more likely 
than Whites to have hypertension and to be prescribed isosorbide dinitrate and diuretics 
(Dickson, Knafl, & Riegel, 2015). Guidelines recommend that the pharmacologic regimen 
for patients with HF include angiotensin-converting-enzyme (ACE) inhibitors, beta blockers 
and angiotensin receptor blockers (Yancy et al., 2013), all medications that lower BP. In 
fact, poor blood pressure control is commonly blamed on medication nonadherence (Hayen, 
Bell, Glasziou, Neal, & Irwig, 2010), and elevated systolic BP is associated with poor 
medication adherence (Braverman & Dedier, 2009; Knafl, Schoenthaler, & Ogedegbe, 
2012). Therefore, our finding that systolic BP is higher among Blacks may be a consequence 
of poor medication adherence rather than a cause of nonadherence.
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The final factor significantly associated with nonadherence in Blacks was the use of fewer 
methods to compensate for feeling confused or forgetful. We used a new measure of the 
methods used by patients to compensate for such feelings. Other researchers have found that 
older adults use internal and external strategies to remember to take their medications 
including visual cues, consistent routines and physical objects (e.g., pill boxes; Gould, 
McDonald-Miszczak, & King, 1997). Such compensatory strategies were associated with 
higher education, more medications, and self-efficacy to take medications, but differences 
by racial group were not explored (Boron, Rogers, & Fisk, 2013). Our finding that lack of 
such methods was a significant risk factor for Blacks requires further exploration. How 
individuals develop or adapt such methods, especially related to medication adherence, may 
help inform future interventions.
Limitations
Interactions were not considered because subgroup sample sizes were unlikely to be large 
enough for interaction analysis. Further, our sample was English-speaking and fairly well-
educated. Further research is needed in an adequately powered sample of persons of color 
that includes non-English-speaking individuals and those with low literacy, groups which 
were not adequately represented in the present study. In this study, measurement of 
adherence was limited to one medication, and new data suggest that some subtle differences 
exist in the adherence to various HF medicines (Viana et al., 2014). These data were 
collected before this article was published, but future studies should monitor a single drug 
class in all participants or preferably all the major drugs in the regimen. A strength of the 
study was the use of objective measures of medication adherence using the MEMS rather 
than relying on self-report or pharmacy data to calculate medication adherence. Self-report 
has been shown to be unreliable, so our method of measuring medication adherence 
strengthens our conclusions.
Conclusions
Although similar patterns of nonadherence have been found by others (Zhang & Baik, 2014) 
our findings suggest that the issue of medication adherence is exceedingly complex for 
many persons with HF, especially Blacks. Many of these patients were taking complex 
medication regimens, with substantial numbers of medications. An individualized approach 
may be needed in order to address the health disparities associated with medication 
nonadherence. Specifically, clinicians should be sensitive to those factors (e.g., multiple 
comorbid conditions) that may place ethnic minorities at increased risk for poor adherence. 
Further research is needed to develop and test interventions that help Black patients with HF 
to manage multiple medications required by multiple chronic conditions. These results also 
reinforce the need to address methods of compensating for forgetfulness when teaching 
Blacks about their medication regimens.
Acknowledgments
This work was funded in part by a grant from the National Heart, Lung & Blood Institute (R01 HL084394-01A1) 
and by the Philadelphia Veterans Affairs Medical Center, VISN 4 Mental Illness Research, Education, and Clinical 
Center (MIREC). The authors gratefully acknowledge Megan Patey for her assistance with preparation of the data 
for analysis.
Dickson et al. Page 12
Res Nurs Health. Author manuscript; available in PMC 2016 August 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
References
Alosco ML, Spitznagel MB, Josephson R, Hughes J, Gunstad J. COPD is associated with cognitive 
dysfunction and poor physical fitness in heart failure. Heart & Lung. 2015; 44:21–26.10.1016/
j.hrtlng.2014.09.002 [PubMed: 25308768] 
Bagchi A, Esposito D, Kim M, Verdier J, Bencio D. Utilization of, and adherence to, drug therapy 
among Medicaid beneficiaries with congestive heart failure. Clinical Therapeutics. 2007; 29:1771–
1783.10.1016/j.clinthera.2007.08.015 [PubMed: 17919558] 
Bahrami H, Kronmal R, Bluemke DA, Olson J, Shea S, Liu K, Lima JA. Differences in the incidence 
of congestive heart failure by ethnicity: the multi-ethnic study of atherosclerosis. Archivesof 
Internal Medicine. 2008; 168:2138–2145.10.1001/archinte.168.19.2138
Bakas T, Pressler S, Johnson E, Nauser J, Shaneyfelt T. Family caregiving in heart failure. Nursing 
Research. 2006; 55:180–188. [PubMed: 16708042] 
Barbaranelli C, Lee C, Vellone E, Riegel B. Dimensionality and reliability the Self-Care of Heart 
Failure Index scales: Further evidence from Confirmatory Factor Analysis. Research in Nursing & 
Health. 2014; 37:524–537.10.1002/nur.21623 [PubMed: 25324013] 
Boron JB, Rogers WA, Fisk AD. Everyday memory strategies for medication adherence. Geriatric 
Nursing. 2013; 34:395–401.10.1016/j.gerinurse.2013.05.010 [PubMed: 23810198] 
Braunstein J, Anderson G, Gerstenblith G, Weller W, Niefeld M, Herbert R, Wu A. Noncardiac 
comorbidity increases preventable hospitalizations and mortality among Medicare beneficiaries 
with chronic heart failure. Journal of the American College of Cardiology. 2003; 42:1226–1233. 
[PubMed: 14522486] 
Braverman J, Dedier J. Predictors of medication adherence for African American patients diagnosed 
with hypertension. Ethnicty & Disease. 2009; 19:396–400.
Brown DW, Haldeman GA, Croft JB, Giles WH, Mensah GA. Racial or ethnic differences in 
hospitalization for heart failure among elderly adults: Medicare, 1990 to 2000. American Heart 
Journal. 2005; 150:448–454.10.1016/j.ahj.2004.11.010 [PubMed: 16169322] 
Bui AL, Horwich TB, Fonarow GC. Epidemiology and risk profile of heart failure. Nature Reviews 
Cardiology. 2011; 8:30–41.10.1038/nrcardio.2010.165 [PubMed: 21060326] 
Charlson M, Pompei P, Ales K, MacKenzie C. A new method of classifying prognostic comorbidity in 
longitudinal studies: development and validation. Journal of Chronic Diseases. 1987; 40:373–383. 
[PubMed: 3558716] 
Dickson V, Buck H, Riegel B. A qualitative meta-analysis of heart failure self-care practices among 
individuals with multiple comorbid conditions. Journal of Cardiac Failure. 2011; 17:413–
419.10.1016/j.cardfail.2010.11.011 [PubMed: 21549299] 
Dickson V, Buck H, Riegel B. Multiple comorbid conditions challenge heart failure self-care by 
decreasing self-efficacy. Nursing Research. 2013; 62:2–9.10.1097/NNR.0b013e31827337b3 
[PubMed: 23052421] 
Dickson V, Deatrick J, Riegel B. A typology of heart failure self-care management in non-elders. 
European Journal of Cardiovascular Nursing. 2008; 7:171–181.10.1016/j.ejcnurse.2007.11.005 
[PubMed: 18178132] 
Dickson V, Knafl G, Riegel B. Racial differences in clinical treatment and self-care behaviors of adults 
with chronic heart failure. Journal of the American Heart Association. 2015; 4:e001561. doi: 
10.1161. [PubMed: 25870187] 
Dickson V, McCarthy M, Howe A, Schipper J, Katz S. Socio-cultural influences on heart failure self-
care among an ethnic minority black population. Journal of Cardiovascular Nursing. 2013; 
28:111–118.10.1097/JCN.0b013e31823db328 [PubMed: 22343210] 
Dinges D, Kribbs N, Bates B, Carlin M. A very brief probed-recall memory task: Sensitivity to sleep 
loss. Sleep Research. 1993; 22:330.
Gheorghiade M, Abraham WT, Albert NM, Gattis Stough W, Greenberg BH, O’Connor CM, Fonarow 
GC. Relationship between admission serum sodium concentration and clinical outcomes in 
patients hospitalized for heart failure: An analysis from the OPTIMIZE-HF registry. European 
Heart Journal. 2007; 28:980–988.10.1093/eurheartj/ehl542 [PubMed: 17309900] 
Dickson et al. Page 13
Res Nurs Health. Author manuscript; available in PMC 2016 August 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Gould ON, McDonald-Miszczak L, King B. Metacognition and medication adherence: how do older 
adults remember? Experimental Aging Research. 1997; 23:315–342.10.1080/03610739708254034 
[PubMed: 9352290] 
Gregory, R. Foundations of intellectual assessment: The WAIS-III and other tests in clinical practice. 
Boston: Allyn and Bacon; 1999. 
Hayen A, Bell K, Glasziou P, Neal B, Irwig L. Monitoring adherence to medication by measuring 
change in blood pressure. Hypertension. 2010; 56:612–616.10.1161/HYPERTENSIONAHA.
110.153817 [PubMed: 20696980] 
Heidenreich P, Albert NM, Allen LA, Bluemke DA, Butler J, Fonarow GC, Trogdon JG. Forecasting 
the impact of heart failure in the United States: A policy statement from the American Heart 
Association. Circulation: Heart Failure. 2013; 6:606–619.10.1161/HHF.0b013e318291329a 
[PubMed: 23616602] 
Hinton-Bayre AD, Geffen G, McFarland K. Mild head injury and speed of information processing: a 
prospective study of professional rugby league players. Journal of Clinical and Experimental 
Neuropsychology. 1997; 19:275–289. [PubMed: 9240486] 
Hosmer, D.; Lemeshow, S. Applied logistic regression. 2. New York: John Wiley & Sons; 2000. 
Johns MW. Reliability and factor analysis of the Epworth Sleepiness Scale. Sleep. 1992; 15:376–381. 
[PubMed: 1519015] 
Joy S, Kaplan E, Fein D. Digit symbol-incidental learning in the WAIS-III: construct validity and 
clinical significance. Clinical Neuropsychology. 2003; 17:182–194.10.1076/clin.17.2.182.16495
Knafl, G.; Delucchi, K.; Bova, C.; Fennie, K.; Ding, K.; Williams, A. A systematic approach for 
analyzing electronically monitored adherence data. Hauppauge, NY: Nova Science Publishers; 
2010. 
Knafl G, Riegel B. What puts heart failure patients at risk for poor medication adherence. Patient 
Preferences & Adherence. 2014; 8:1007–1018.10.2147/PPA.S64593
Knafl G, Schoenthaler A, Ogedegbe G. Secondary analysis of electronically monitored medication 
adherence data for a cohort of hypertensive African-Americans. Patient Preferences & Adherence. 
2012; 6:207–219.10.2147/ppa.s30582
Koelling TM, Johnson ML, Cody RJ, Aaronson KD. Discharge education improves clinical outcomes 
in patients With chronic heart failure. Circulation. 2005; 111:179–185.10.1161/01.cir.
0000151811.53450.b8 [PubMed: 15642765] 
Kroenke K, Spitzer R, Williams J. The PHQ-9: Validity of a brief depression severity measure. Journal 
of General Internal Medicine. 2001; 16:606–613. [PubMed: 11556941] 
Lezak, MD.; Howieson, DB.; Loring, DW. Neuropsychological assessment. 4. New York: Oxford 
University Press; 2004. 
MacLaughlin EJ, Raehl CL, Treadway AK, Sterling TL, Zoller DP, Bond CA. Assessing medication 
adherence in the elderly: Which tools to use in clinical practice? Drugs & Aging. 2005; 22:231–
255. [PubMed: 15813656] 
Masoudi F, Rumsfeld J, Havranek E, House J, Peterson E, Krumholz H, Spertus J. Age, functional 
capacity, and health-related quality of life in patients with heart failure. Journal of Cardiac Failure. 
2004; 10:368–373. [PubMed: 15470645] 
Mastromarino V, Casenghi M, Testa M, Gabriele E, Coluccia R, Rubattu S, Volpe M. Polypharmacy 
in heart failure patients. Current Heart Failure Reports. 2014; 11:212–219.10.1007/
s11897-014-0186-8 [PubMed: 24493574] 
Miller LA, Spitznagel MB, Alosco ML, Cohen RA, Raz N, Sweet LH, Gunstad J. Cognitive profiles in 
heart failure: A cluster analytic approach. Journal of Clinical and Experimental Neuropsychology. 
2012; 34:509–520.10.1080/13803395.2012.663344 [PubMed: 22375800] 
Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, Turner MB. Heart disease 
and stroke statistics—2015 update: A report from the American Heart Association. Circulation. 
2014; 131:e29–322.10.1161/cir.0000000000000152 [PubMed: 25520374] 
Nichols-English G, Poirier S. Optimizing adherence to pharmaceutical care plans. Journal of the 
American Pharmaceutical Association. 2000; 40:475–485. [PubMed: 10932456] 
Reitan RM. The relation of the trail making test to organic brain damage. Journal of Consulting 
Psychology. 1955; 19:393–394. [PubMed: 13263471] 
Dickson et al. Page 14
Res Nurs Health. Author manuscript; available in PMC 2016 August 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Reitan, RM. Trail Making Test. Tucson, AZ: Reitan Neuropsychological Laboratory; 1992. 
Riegel B, Knafl GJ. Electronically monitored medication adherence predicts hospitalization in heart 
failure patients. Patient Preferences & Adherence. 2013; 8:1–13.10.2147/PPA.S54520
Riegel B, Lee C, Dickson V, Carlson B. An update on the Self-Care of Heart Failure Index. Journal of 
Cardiovascular Nursing. 2009; 24:485–497.10.1097/JCN.0b013e3181b4baa0 [PubMed: 
19786884] 
Riegel B, Lee C, Ratcliffe S, De Geest S, Potashnik S, Patey M, Weintraub W. Predictors of 
objectively measured medication nonadherence in adults with heart failure. Circulation: Heart 
Failure. 2012; 5:430–436.10.1161/circheartfailure.111.965152 [PubMed: 22647773] 
Riegel B, Moelter S, Ratcliffe S, Pressler SJ, De Geest S, Potashnik S, Goldberg LR. Excessive 
daytime sleepiness is associated with poor medication adherence in adults with heart failure. 
Journal of Cardiac Failure. 2011; 17:340–348.10.1016/j.cardfail.2010.11.002 [PubMed: 
21440873] 
Sabate, E. Adherence to long-term therapies: Evidence for action. Geneva: World Health 
Organization; 2003. 
Schocken D, Benjamin E, Fonarow G, Krumholz H, Levy D, Mensah G, Hong Y. Prevention of heart 
failure: A scientific statement from the American Heart Association Councils on Epidemiology 
and Prevention, Clinical Cardiology, Cardiovascular Nursing, and High Blood Pressure Research; 
Quality of Care and Outcomes Research Interdisciplinary Working Group; and Functional 
Genomics and Translational Biology Interdisciplinary Working Group. Circulation. 2008; 
117:2544–2565.10.1161/circulationaha.107.188965 [PubMed: 18391114] 
Serber SL, Kumar R, Woo MA, Macey PM, Fonarow GC, Harper RM. Cognitive test performance and 
brain pathology. Nursing Research. 2008; 57:75–83.10.1097/01.nnr.0000313483.41541.10 
[PubMed: 18347478] 
Silva M. Development of the WAIS-III: Brief overview, history and description. Graduate Journal of 
Counseling Psychology. 2008; 1:117–135.
Sullivan M, Newton K, Hecht J, Russo J, Spertus J. Depression and health status in elderly patients 
with heart failure: A 6-month prospective study in primary care. American Journal of Geriatric 
Cardiology. 2004; 13:252–260. [PubMed: 15365288] 
Van der Wal M, Jaarsma T. Adherence in heart failure in the elderly: Problem and possible solutions. 
[Review]. International Journal of Cardiology. 2008; 125:203–208.10.1016/j.ijcard.2007.10.011 
[PubMed: 18031843] 
Viana M, Laszczynska O, Mendes S, Frioes F, Lourenco P, Bettencourt P, Azevedo A. Medication 
adherence to specific drug classes in chronic heart failure. Journal of Managed Care Pharmacy. 
2014; 20:1018–1026.
Wagner S, Helmreich I, Dahmen N, Lieb K, Tadic A. Reliability of three alternate forms of the Trail 
Making Tests A and B. Archives in Clinical Neuropsychology. 2011; 26:314–321.10.1093/arclin/
acr024
Wald N, Law M. A strategy to reduce cardiovascular disease by more than 80 %. BMJ. 2003; 
326(7404):1419. doi: http://dx.doi.org/10.1136/bmj.326.7404.1419. [PubMed: 12829553] 
Wechsler, D. WAIS-III: Administration and scoring manual. 3. San Antonio, TX: Psychological 
Corporation; 1997. 
Wu J, Moser D, Chung M, Lennie T. Objectively measured, but not self-reported, medication 
adherence independently predicts event-free survival in patients with heart failure. Journal of 
Cardiac Failure. 2008a; 14:203–210.10.1016/j.cardfail.2007.11.005 [PubMed: 18381183] 
Wu J, Moser D, Chung M, Lennie T. Predictors of medication adherence using a multidimensional 
adherence model in patients with heart failure. Journal of Cardiac Failure. 2008b; 14:603–
614.10.1016/j.cardfail.2008.02.011 [PubMed: 18722327] 
Wu J, Moser D, De Jong M, Rayens M, Chung M, Riegel B, Lennie T. Defining an evidence-based 
cutpoint for medication adherence in heart failure. American Heart Journal. 2009; 157:285–
291.10.1016/j.ahj.2008.10.001 [PubMed: 19185635] 
Wu J, Moser D, Lennie T, Burkhart P. Medication adherence in patients who have heart failure: A 
review of the literature. Nursing Clinics of North America. 2008; 43:133–153.10.1016/j.cnur.
2007.10.006 [PubMed: 18249229] 
Dickson et al. Page 15
Res Nurs Health. Author manuscript; available in PMC 2016 August 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Wu J, Moser D, Lennie T, Peden A, Yu-Chang C, Heo S. Factors influencing medication adherence in 
patients with heart failure. Heart & Lung. 2008; 37:8–16.10.1016/j.hrtlng.2007.02.003 [PubMed: 
18206522] 
Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, American College of Cardiology Foundation/
American Heart Association Task Force on Practice, G. 2013 ACCF/AHA guideline for the 
management of heart failure: A report of the American College of Cardiology Foundation/
American Heart Association Task Force on practice guidelines. Circulation. 2013; 128:e240–
327.10.1161/CIR.0b013e31829e8776 [PubMed: 23741058] 
Zhang Y, Baik S. Race/ethnicity, disability, and medication adherence among Medicare beneficiaries 
with heart failure. Journal of General Internal Medicine. 2014; 29:602–607.10.1007/
s11606-013-2692-x [PubMed: 24366395] 
Zimet G. Multidimensional Scale of Perceived Social Support. Journal of Personality Assessment. 
1988; 52:30–41.
Zimet, G.; Dahlem, N.; Zimet, S.; Farley, G. Multidimensional Scale of Perceived Social Support. In: 
Fischer, J.; Corcoran, K., editors. Measures for clinical practice: A sourcebook. Volume 2: Adults. 
2. New York: Free Press; 1994. p. 393-394.
Zimet G, Powell S, Farley G, Werkman S, Berkoff K. Psychometric characteristics of the 
Multidimensional Scale of Perceived Social Support. Journal of Personality Assessment. 1990; 
55:610–617.10.1080/00223891.1990.9674095 [PubMed: 2280326] 
Dickson et al. Page 16
Res Nurs Health. Author manuscript; available in PMC 2016 August 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Dickson et al. Page 17
Ta
bl
e 
1
Co
m
pa
ris
on
 o
f D
em
og
ra
ph
ic
 V
ar
ia
bl
es
 in
 B
la
ck
 a
nd
 W
hi
te
 P
ar
tic
ip
an
ts 
w
ith
 H
ea
rt 
Fa
ilu
re
Bl
ac
k 
(n
=
63
)
W
hi
te
 (n
=
14
9)
V
ar
ia
bl
e
C
at
eg
or
ie
s o
r O
bs
er
ve
d 
R
an
ge
n
 
(%
)
M
ea
n 
(S
D
)
n
 
(%
)
M
ea
n 
(S
D
)
pa
Em
pl
oy
m
en
t s
ta
tu
s
R
et
ire
d
32
 (5
0.8
)
63
 (4
2.3
)
.
02
5
U
ne
m
pl
oy
ed
 o
r d
isa
bl
ed
22
 (3
4.9
)
38
 (2
5.5
)
Em
pl
oy
ed
 (f
ull
 or
 pa
rt 
tim
e)
9 
(14
.3)
48
 (2
5.5
)
G
en
de
r
M
al
e
38
 (6
0.3
)
98
 (6
5.8
)
.
44
9
Fe
m
al
e
25
 (3
9.7
)
51
 (3
4.2
)
In
co
m
e
D
o 
no
t h
av
e 
en
ou
gh
23
 (3
6.5
)
12
 (8
.1)
<
.0
01
H
av
e 
en
ou
gh
 o
r m
or
e
40
 (6
3.5
)
13
7 
(91
.9)
In
su
ra
nc
e
G
ov
er
nm
en
t o
r n
on
eb
43
 (6
8.3
)
74
 (4
9.7
)
.
01
3
Co
m
m
er
ci
al
 o
r H
M
O
20
 (3
1.7
)
75
 (5
0.3
)
M
ar
ita
l s
ta
tu
s
Si
ng
le
, d
iv
or
ce
d,
 se
pa
ra
te
d,
 o
r w
id
ow
ed
40
 (6
3.5
)
47
 (3
1.5
)
<
.0
01
M
ar
rie
d 
or
 p
ar
tn
er
ed
23
 (3
6.5
)
10
2 
(68
.5)
A
ge
30
–8
9
61
.7
 (1
0.5
)
63
.4
 (1
2.0
)
.
32
1
Y
ea
rs
 o
f e
du
ca
tio
n
8–
29
13
.0
 (2
.2)
14
.5
 (3
.1)
.
00
1
No
te
.
 
H
M
O
= 
he
al
th
 m
ai
nt
en
an
ce
 o
rg
an
iz
at
io
n;
 S
D
=
 s
ta
nd
ar
d 
de
vi
at
io
n.
a
U
sin
g 
χ2
 
o
r 
t t
es
t f
or
 d
iff
er
en
ce
s b
et
w
ee
n 
Bl
ac
ks
 a
nd
 W
hi
te
s a
s a
pp
ro
pr
ia
te
.
b O
nl
y 
2 
(0.
9%
) o
f t
he
 21
2 p
art
ici
pa
nts
 ha
d n
o i
ns
ura
nc
e, 
so
 th
ey
 w
ere
 co
mb
ine
d w
ith
 pa
rti
cip
an
ts 
wi
th 
go
ve
rnm
en
t in
su
ran
ce
.
Res Nurs Health. Author manuscript; available in PMC 2016 August 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Dickson et al. Page 18
Ta
bl
e 
2
Co
m
pa
ris
on
 o
f C
lin
ic
al
 V
ar
ia
bl
es
 in
 B
la
ck
 a
nd
 W
hi
te
 P
ar
tic
ip
an
ts 
w
ith
 H
ea
rt 
Fa
ilu
re
V
ar
ia
bl
e
C
at
eg
or
ie
s o
r O
bs
er
ve
d 
ra
ng
e
Bl
ac
k 
(n
=
63
)
W
hi
te
 (n
=
14
9)
n
 
(%
)
M
ea
n 
(S
D
)
n
 
(%
)
M
ea
n 
(S
D
)
p 
a
Pr
es
cr
ib
ed
 m
ed
ic
at
io
n 
ra
te
 m
ed
ic
at
io
n 
co
nt
ro
lle
d 
by
 M
EM
S
2–
3
39
 (6
1.9
)
92
 (6
1.7
)
.
98
3
1
24
 (3
8.1
)
57
 (3
8.3
)
G
en
er
al
 h
ea
lth
 p
er
ce
pt
io
n
Po
or
13
 (2
0.6
)
11
 (7
.4)
0.
00
5
Fa
ir 
to
 e
xc
el
le
nt
50
 (7
9.4
)
13
8 
(92
.6)
H
ea
lth
 c
om
pa
re
d 
to
 a
 y
ea
r a
go
Po
or
8 
(12
.7)
9 
(6.
0)
.
10
4
Fa
ir 
to
 e
xc
el
le
nt
55
 (8
7.3
)
14
0 
(94
.0)
N
Y
H
A
 c
la
ss
IV
24
 (3
8.1
)
16
 (1
0.7
)
<
.0
01
I–
II
I
39
 (6
1.9
)
13
3 
(89
.3)
Ch
ar
lso
n 
to
ta
l
1–
11
3.
0 
(2.
0)
2.
6 
(1.
6)
.
09
9
N
um
be
r o
f c
om
or
bi
di
tie
s
0–
9
3.
7 
(1.
9)
2.
8 
(2.
1)
.
00
2
Eje
cti
on
 fr
act
ion
5–
80
35
.5
b  
(19
.2)
35
.9
 (1
6.5
)
.
90
8
M
on
th
s s
in
ce
 h
ea
rt 
fa
ilu
re
 d
ia
gn
os
is
0–
50
8
75
.0
c  
(62
.9)
76
.1
e  
(80
.9)
.
92
7
To
ta
l m
ed
ic
at
io
ns
2–
25
11
.0
d  
(3.
4)
9.
5 
(3.
9)
.
00
9
To
ta
l d
os
es
 (m
ed
ica
tio
ns
)
4–
29
15
.1
 (5
.4)
12
.5
 (5
.5)
.
00
3
No
te
.
 
M
EM
S=
 M
ed
ic
at
io
n 
Ev
en
t M
on
ito
rin
g 
Sy
ste
m
; N
Y
H
A
= 
N
ew
 Y
or
k 
H
ea
rt 
A
ss
oc
ia
tio
n;
 S
D
=
 s
ta
nd
ar
d 
de
vi
at
io
n.
a
U
sin
g 
χ2
 
o
r 
t t
es
t f
or
 d
iff
er
en
ce
s b
et
w
ee
n 
Bl
ac
ks
 a
nd
 W
hi
te
s a
s a
pp
ro
pr
ia
te
.
b n
 
=
 6
2
c n
 
=
 6
1
d n
 
=
 5
3
e n
 
=
 1
36
Res Nurs Health. Author manuscript; available in PMC 2016 August 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Dickson et al. Page 19
Ta
bl
e 
3
R
isk
 F
ac
to
r M
od
el
s f
or
 M
ed
ic
at
io
n 
N
on
ad
he
re
nc
e 
in
 B
la
ck
 P
ar
tic
ip
an
ts 
w
ith
 H
ea
rt 
Fa
ilu
re
 th
at
 w
er
e 
Si
gn
ifi
ca
nt
 in
 B
iv
ar
ia
te
 A
na
ly
se
s
V
ar
ia
bl
e t
yp
e
V
ar
ia
bl
e
R
isk
 F
ac
to
r
n
 
(%
)a
O
R
p
95
%
 C
I
D
em
og
ra
ph
ic
s
A
ge
≥ 
74
11
 (1
7.5
)
4.
75
.
02
6
1.
28
–1
8.
7
So
ci
al
 su
pp
or
t
Li
ve
 a
lo
ne
ye
s
21
 (3
3.3
)
3.
52
.
02
7
1.
16
–1
0.
7
M
SP
SS
 S
co
re
≤ 
80
 (v
s. 
> 8
0 o
r m
iss
ing
)
46
 (7
3.0
)
5.
28
.
04
0
1.
08
–2
5.
8
Cl
in
ic
al
B
lo
od
 u
re
a 
ni
tro
ge
nb
≥ 
39
8 
(12
.7)
8.
00
.
01
7
1.
45
–4
4.
1
Ch
ar
lso
n 
to
ta
l
≥ 
4
18
 (2
8.6
)
5.
50
.
00
5
1.
69
–1
7.
9
N
um
be
r o
f c
om
or
bi
di
tie
sc
≥ 
6
9 
(14
.3)
10
.0
.
00
7
1.
85
–5
3.
9
Cr
ea
tin
in
eb
≥ 
2.
3
8 
(12
.7)
8.
00
.
01
7
1.
45
–4
4.
1
Se
ru
m
 so
di
um
≤ 
14
0 
(vs
. >
 14
0 o
r m
iss
ing
)
40
 (6
3.5
)
5.
46
.
01
5
1.
39
–2
1.
3
Sy
sto
lic
 b
lo
od
 p
re
ss
ur
e
≥ 
13
5 
(vs
. <
 13
5 o
r m
iss
ing
)
13
 (2
0.6
)
4.
56
.
02
1
1.
26
–1
6.
4
Se
lf-
ca
re
SC
H
FI
 m
ai
nt
en
an
ce
≤ 
72
 (v
s. 
> 7
2 o
r m
iss
ing
)
43
 (6
8.3
)
4.
08
.
04
4
1.
04
–1
6.
0
Sy
m
pt
om
s
PH
Q 
tot
ald
≥ 
9
9 
(14
.3)
5.
20
.
03
2
1.
15
–2
3.
5
Co
gn
iti
on
CA
S 
sc
or
e
≤ 
7
21
 (3
3.3
)
4.
89
.
00
6
1.
57
–1
5.
2
D
SS
T 
sc
or
e
≤ 
29
11
 (1
7.5
)
4.
75
.
02
6
1.
20
–1
8.
7
TI
CS
 sc
or
e
≤ 
30
21
 (3
3.3
)
3.
19
.
05
0
1.
00
–1
0.
1
TM
TA
 sc
or
ed
≥ 
77
9 
(14
.3)
5.
20
.
03
2
1.
15
–2
3.
5
TM
TB
 sc
or
ec
≥ 
20
1 
(vs
. <
 20
1 o
r m
iss
ing
)
9 
(14
.3)
10
.0
.
00
7
1.
85
–5
3.
9
No
te
. O
R=
 o
dd
s r
at
io
, C
I=
 c
o
n
fid
en
ce
 in
te
rv
al
, C
A
S=
 C
om
pe
ns
at
or
y 
A
ct
iv
iti
es
 S
co
re
; D
SS
T=
 D
ig
it 
Sy
m
bo
l S
ub
sti
tu
tio
n 
Te
st,
 M
SP
SS
= 
M
ul
tid
im
en
sio
na
l S
ca
le
 o
f P
er
ce
iv
ed
 S
oc
ia
l S
up
po
rt;
 P
H
Q=
 Pa
tie
nt 
H
ea
lth
 Q
ue
sti
on
na
ire
; S
CH
FI
= S
elf
-C
are
 of
 H
ea
rt 
Fa
ilu
re 
Ind
ex
; T
IC
S=
 T
ele
ph
on
e I
nte
rvi
ew
 fo
r C
og
nit
ive
 St
atu
s; 
TM
TA
= T
rai
l M
ak
ing
 T
est
 – 
A;
 T
M
TB
= T
rai
l M
ak
ing
 T
est
 – 
B.
a
O
ut
 o
f 6
3 
Bl
ac
k 
pa
rti
ci
pa
nt
s w
ith
 M
ed
ic
at
io
n 
Ev
en
t M
on
ito
rin
g 
Sy
ste
m
 d
at
a.
b T
he
 e
sti
m
at
es
 a
re
 th
e 
sa
m
e 
fo
r t
he
se
 tw
o 
va
ria
bl
es
 b
ec
au
se
 th
ey
 c
or
re
sp
on
d 
to
 sa
m
e 
se
t o
f p
ar
tic
ip
an
ts.
c A
lth
ou
gh
 th
e 
es
tim
at
es
 a
re
 th
e 
sa
m
e 
fo
r t
he
se
 tw
o 
va
ria
bl
es
, t
he
y 
co
rre
sp
on
d 
to
 d
iff
er
en
t s
et
s o
f p
ar
tic
ip
an
ts.
d A
lth
ou
gh
 th
e 
es
tim
at
es
 a
re
 th
e 
sa
m
e 
fo
r t
he
se
 tw
o 
va
ria
bl
es
, t
he
y 
co
rre
sp
on
d 
to
 d
iff
er
en
t s
et
s o
f p
ar
tic
ip
an
ts.
Res Nurs Health. Author manuscript; available in PMC 2016 August 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Dickson et al. Page 20
Ta
bl
e 
4
M
ul
tip
le
 R
isk
 F
ac
to
rs
 M
od
el
 o
f M
ed
ic
at
io
n 
N
on
ad
he
re
nc
e 
in
 B
la
ck
 P
ar
tic
ip
an
ts 
w
ith
 H
ea
rt 
Fa
ilu
re
V
ar
ia
bl
e T
yp
e
V
ar
ia
bl
e
R
isk
 F
ac
to
r
n
 
in
 R
isk
 G
ro
up
 (%
)a
O
R
p
95
%
 C
I
D
em
og
ra
ph
ic
–
So
ci
al
 su
pp
or
t
–
Cl
in
ic
al
Co
m
or
bi
di
tie
s
≥ 
6
9 
(14
.3)
11
.9
.
00
9
1.
86
–7
6.
7
Se
ru
m
 so
di
um
≤ 
13
9
36
 (5
2.2
)
8.
2
.
02
3
1.
34
–5
0.
5
Sy
sto
lic
 b
lo
od
 p
re
ss
ur
e
≥ 
13
5
13
 (2
0.6
)
10
.8
.
00
8
1.
89
–6
2.
3
Se
lf-
ca
re
–
Sy
m
pt
om
–
Co
gn
iti
on
CA
S 
sc
or
e
≤ 
7
21
 (3
3.3
)
7.
21
.
02
5
1.
29
–4
.0
4
No
te
.
 
CA
S 
= 
Co
m
pe
ns
at
or
y 
A
ct
iv
iti
es
 S
co
re
; O
R 
=
 o
dd
s r
at
io
; C
I =
 c
o
n
fid
en
ce
 in
te
rv
al
.
a
O
ut
 o
f 6
3 
Bl
ac
k 
pa
rti
ci
pa
nt
s w
ith
 M
ed
ic
at
io
n 
Ev
en
t M
on
ito
rin
g 
Sy
ste
m
 d
at
a.
Res Nurs Health. Author manuscript; available in PMC 2016 August 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Dickson et al. Page 21
Ta
bl
e 
5
R
isk
 F
ac
to
r M
od
el
s f
or
 M
ed
ic
at
io
n 
N
on
ad
he
re
nc
e 
in
 W
hi
te
 P
ar
tic
ip
an
ts 
w
ith
 H
ea
rt 
Fa
ilu
re
 th
at
 w
er
e 
Si
gn
ifi
ca
nt
 in
 B
iv
ar
ia
te
 A
na
ly
se
s
V
ar
ia
bl
e T
yp
e
V
ar
ia
bl
e
R
isk
 F
ac
to
r
n
 (%
)a
O
R
p
95
%
 C
I
D
em
og
ra
ph
ic
s
A
ge
≥ 
61
94
 (6
3.1
)
3.
18
.
00
9
1.
34
–7
.5
2
So
ci
al
 su
pp
or
t
–
Cl
in
ic
al
Co
m
or
bi
di
tie
s
≥ 
4
50
 (3
3.6
)
2.
15
.
04
4
1.
02
–4
.5
1
M
on
th
s s
in
ce
 h
ea
rt 
fa
ilu
re
 d
ia
gn
os
is
≥ 
15
3 
(vs
. <
 15
3 o
r m
iss
ing
)
19
 (1
2.8
)
2.
76
.
04
4
1.
03
–7
.3
8
To
ta
l d
os
es
 (m
ed
ica
tio
n)
≥ 
11
 (v
s. 
< 1
1 o
r m
iss
ing
)
83
 (5
5.7
)
2.
42
.
02
5
1.
12
–5
.2
3
Se
lf-
ca
re
–
Sy
m
pt
om
s
–
Co
gn
iti
on
TM
TB
 sc
or
e
≥ 
93
66
 (4
4.3
)
2.
22
.
03
3
1.
07
–4
.6
1
No
te
. C
I =
 c
o
n
fid
en
ce
 in
te
rv
al
; O
R 
=
 o
dd
s r
at
io
; T
M
TB
 =
 T
ra
il 
M
ak
in
g 
Te
st 
– 
B.
a
O
ut
 o
f 1
49
 W
hi
te
 p
ar
tic
ip
an
ts 
w
ith
 M
ed
ic
at
io
n 
Ev
en
t M
on
ito
rin
g 
Sy
ste
m
 d
at
a.
Res Nurs Health. Author manuscript; available in PMC 2016 August 01.
